Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07213895) titled 'Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy(R) XR Extended Release Film Coated Tablets' on Oct. 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: None (Open Label).
Primary Sponsor: Humanis Saglik Anonim Sirketi
Condition:
Type 2 Diabetes Mellitus (T2DM)
Intervention:
Drug: Empagliflozin/Linagliptin/Metformin HCL
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: May 21, 2025
Target Sample Size: 14
Coun...